biostudies-literatureUnknown8(3)Galvao DA<h4>Importance</h4>Sexual dysfunction is a common adverse effect of prostate cancer treatment, and current management strategies do not adequately address physical and psychological causes. Exercise is a potential therapy in the management of sexual dysfunction.<h4>Objective</h4>To investigate the effects of supervised, clinic-based, resistance and aerobic exercise with and without a brief psychosexual education and self-management intervention (PESM) on sexual function in men with prostate cancer compared with usual care.<h4>Design, setting, and participants</h4>A 3-arm, parallel-group, single-center randomized clinical trial was undertaken at university-affiliated exercise clinics between July 24, 2014, and August 22, 2019. Eligible participants were men with prostate cancer who had prevJAMA network opene250413https://www.ebi.ac.uk/biostudies/studies/S-EPMC11904736biostudies-literatureExercise and Psychosexual Education to Improve Sexual Function in Men With Prostate Cancer: A Randomized Clinical Trial.PMC11904736Taaffe DRNewton RUGardiner RATang CSchumacher OChee RLuo HCormie PSpry NChambers SKNelson CJGalvao DAJoseph DHayne DfalseExercise and Psychosexual Education to Improve Sexual Function in Men With Prostate Cancer: A Randomized Clinical Trial.<h4>Importance</h4>Sexual dysfunction is a common adverse effect of prostate cancer treatment, and current management strategies do not adequately address physical and psychological causes. Exercise is a potential therapy in the management of sexual dysfunction.<h4>Objective</h4>To investigate the effects of supervised, clinic-based, resistance and aerobic exercise with and without a brief psychosexual education and self-management intervention (PESM) on sexual function in men with prostate cancer compared with usual care.<h4>Design, setting, and participants</h4>A 3-arm, parallel-group, single-center randomized clinical trial was undertaken at university-affiliated exercise clinics between July 24, 2014, and August 22, 2019. Eligible participants were men with prostate cancer who had prev2025-01-01T00:00:00Z2025 Mar2025-04-04T00:08:28.674Z2025-04-04T00:08:28.674ZS-EPMC119047364007243710.1001/jamanetworkopen.2025.0413